Anaplastic Large Cell Lymphoma: Crizotinib Approved for Younger Patients

Crizotinib (Xalkori®, Pfizer) is now FDA approved for the treatment of pediatric patients age one year and older and young adult patients with relapsed/refractory systemic ALK-positive anaplastic large cell lymphoma (ALCL). The approval was based on Study ADVL0912 (NCT00939770), a single-arm phase 1/2 trial. "Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as ALCL, inflammatory myofibroblastic tumors, non-small cell lung cancer (NSCLC), and neurob...
Continue reading

Umbralisib/Ublituximab Improves Survival in Chronic Lymphocytic Leukemia

In patients with treatment-naive or relapsed/refractory chronic lymphocytic leukemia (CLL), the combination of umbralisib and ublituximab significantly increases progression-free survival (PFS) compared with obinutuzumab/chlorambucil, according to results of a phase 3 trial recently presented at the American Society of Hematology (ASH) Annual Meeting. "Umbralisib is an oral, once-daily, novel dual inhibitor of phosphatidylinositol-3-kinase-delta (PI3Kδ) and casein kinase-1ε (CK1ε) that exhibits ...
Continue reading

CC-486 Effective for Acute Myeloid Leukemia

The oral hypomethylating agent CC-486, when administered in an escalated dosing schedule (>7 days per 28-day treatment cycle), has been shown to be effective and well tolerated for patients with acute myeloid leukemia (AML) experiencing their first relapse, according to results of a study presented at American Society of Hematology (ASH) Annual Meeting. For the phase 3 international, randomized, double-blind QUAZAR AML-001 trial (NCT01757535), 472 patients with AML were enrolled. To be eligib...
Continue reading

Hagop Kantarjian, MD: Inotuzumab Ozogamicin for Relapsed/Refractory Ph-Positive Acute Lymphoblastic Leukemia

Among patients with relapsed/refractory acute lymphoblastic leukemia (ALL), those with Philadelphia chromosome (Ph)-positive disease experience a higher rate of relapse and poorer chances of long-term survival. According to results of the phase 3 INO-VATE trial recently published in Cancer, inotuzumab ozogamicin, a humanized anti-CD22 monoclonal antibody, achieved high rates of response, remission, and progression-free survival in patients with this disease. In this interview with i3 Health, Hag...
Continue reading

Inotuzumab Ozogamicin Effective in Ph-Positive Acute Lymphoblastic Leukemia

In patients with relapsed/refractory Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), inotuzumab ozogamicin increases rates of response, remission, hematopoietic stem cell transplantation (HSCT), and progression-free survival compared with intensive chemotherapy, although it does not produce a significant improvement in overall survival. "Historically, patients with Ph-positive ALL have had poorer prognoses, with higher rates of relapse and worse long-term survival ...
Continue reading

Copyright © 2021 Oncology Data Advisor. All rights reserved.